|
Title
|
|
|
|
R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| In this study the antiviral activity of a panel of 18 out of 240 pyridazinamine analogues was evaluated against the Sabin strains of the three poliovirus types. We found one compound, R75761 which had a comparable 50% effective concentration (EC50) value against all three poliovirus Sabin strains. Virus multiplication was reduced by 104.0-fold, 106.2-fold and 106.6-fold for poliovirus type 1, type 2 and type 3, respectively. R75761 could be considered as a lead compound for development of anti-poliovirus drugs to be used during the late stage of poliovirus eradication and beyond. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Antiviral research. - Amsterdam
|
|
|
Publication
|
|
|
|
Amsterdam
:
2008
|
|
|
ISSN
|
|
|
|
0166-3542
|
|
|
DOI
|
|
|
|
10.1016/J.ANTIVIRAL.2008.01.002
|
|
|
Volume/pages
|
|
|
|
78
:3
(2008)
, p. 278-281
|
|
|
ISI
|
|
|
|
000255383300013
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|